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A retrospective analysis was performed to evaluate the prognostic significance of peritoneal cytology in patients with endometrial
carcinoma limited to the uterus. A total of 280 patients with surgically staged endometrial carcinoma that was histologically confined
to the uterus were examined clinicopathologically. The median length of follow-up was 62 (range, 12–135) months. All patients
underwent hysterectomy and salpingo-oophorectomy with selective lymphadenectomy, and only three patients received adjuvant
postoperative therapy. No preoperative adjuvant therapy was employed. In all, 48 patients (17%) had positive peritoneal cytology.
The 5-year survival rate among patients with positive or negative peritoneal cytology was 91 or 95%, respectively, showing no
significant difference (log-rank, P¼0.42). The disease-free survival rate at 36 months was 90% among patients with positive cytology,
compared with that of 94% among patients with negative cytology, and the difference was not significant (log-rank, P¼0.52).
Multivariate proportional hazards model revealed only histologic grade to be an independent prognostic factor of survival
(P¼0.0003, 95% CI 3.02 – 40.27) among the factors analysed (age, peritoneal cytology, and depth of myometrial invasion).
Multivariate analysis revealed that histologic grade (P¼0.02, 95% CI 1.21–9.92) was also the only independent prognostic factor of
disease-free survival. We concluded that the presence of positive peritoneal cytology is not an independent prognostic factor in
patients with endometrial carcinoma confined to the uterus, and adjuvant therapy does not appear to be beneficial in these patients.
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Malignant peritoneal cytology is recognised as an adverse
prognostic factor in some gynaecologic malignancies. In ovarian
cancer, there is a general consensus that postoperative adjuvant
chemotherapy should be given to patients with positive peritoneal
cytology even if the tumour is limited to the ovaries, that is, the
International Federation of Gynecology and Obstetrics (FIGO)
stage IC.
As for the positive prognostic value of peritoneal cytology in
endometrial carcinoma confined to the uterus, there is still
controversy, and conflicting results have appeared in the literature.
Accordingly, there is no evidence as to the indication for and
efficacy of adjuvant treatment in the case of positive peritoneal
cytology. Several studies have reported the prognostic value of
positive cytology, and proposed various modalities of adjuvant
therapy, that is, multiagent chemotherapy, progestins, whole
abdominal radiation, and intraperitoneal radioactive chromic
phosphate (
32P) (McLellan et al, 1989; Lurain, 1992). On the other
hand, investigators who found that malignant peritoneal cytology
has poor prognostic value, found that adjuvant therapy was not
beneficial (Yazigi et al, 1983; Konski et al, 1988; Lurain et al, 1989;
Kadar et al, 1992). The question of the prognostic significance of
malignant cytology in endometrial carcinoma confined to the
uterus remains unanswered.
This retrospective clinicopathological study was undertaken to
identify the prognostic significance of positive peritoneal cytology
in endometrial carcinoma confined to the uterus.
PATIENTS AND METHODS
Patients
We reviewed the medical records and the cytologic and pathologic
materials that had been obtained from 392 patients with surgically
treated endometrial carcinoma at the Gynecology Division of the
National Cancer Center Hospital, Tokyo, between 1990 and 1998.
This study included patients who met the following criteria: the
patient underwent primary surgery consisting of total abdominal
hysterectomy and salpingo-oophorectomy with selective pelvic
and/or para-aortic lymphadenectomy; the patient had no histolo-
gic evidence of extrauterine disease; peritoneal cytology was
determined in a peritoneal washing obtained by laparotomy
immediately upon entering the peritoneal cavity during primary
surgery; and the patient had a histologic subtype of endometrioid
adenocarcinoma or adenosquamous carcinoma. Patients with
uncommon histologic subtypes (mucinous, serous, clear cell,
and/or squamous cell carcinoma), and those who had other
simultaneous primary malignancy were excluded. All of the
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ypatients were surgically staged according to the FIGO staging
system (1988), and histologic typing was evaluated according to
the criteria of the WHO International Histologic Classification of
Tumors.
Cytopathology
Cytological specimens were obtained by laparotomy upon
entering the peritoneal cavity immediately before the primary
surgery. Approximately 30ml of sterile saline was instilled
into the pelvis over the uterus, and then aspirated in the
cul-de-sac. When a sufficient amount of ascites was present,
the fluid was removed with a 20–30-ml syringe. The samples
were subjected to cytocentrifugation onto slide glasses at 1700rpm
for 60s at room temperature. The slides were then fixed in
95% ethanol, followed by Papanicolau stain, and alcian blue
stain. Additional slides were stained immunocytochemically
for CEA (Mochida, CEA010, Tokyo, Japan), and also for epithe-
lial antigen defined by an antibody BerEP4 (DAKOPATTS,
Glostrup, Denmark). Two to three cytotechnologists and cyto-
pathologists independently examined all the slides to make a
consensus diagnosis. A patient was considered to have positive
peritoneal cytology if adenocarcinoma cells were detected regard-
less of the number of cancer cells. In this study, in cases where
atypical cells were present but could not be definitively identified
as cancer cells, the peritoneal cytology was considered to be
negative.
Treatment
Our standard primary treatment for early-stage endometrial
carcinoma was surgery consisting of extrafascial total abdominal
simple hysterectomy, bilateral salpingo-oophorectomy and selec-
tive pelvic and/or para-aortic lymphadenectomy. In cases in which
preoperative endometrial biopsy revealed histologic grade 1
tumour and no macroscopic myometrial invasion was found
during the operation, lymphadenectomy was not performed. Para-
aortic lymphadenectomy was performed if para-aortic node
metastasis was diagnosed by pathologic sampling during the
operation. Preoperative adjuvant therapy was not employed in any
patient, and postoperative adjuvant therapy was not indicated for
patients with limited disease.
The primary diagnosis of endometrial carcinoma was made by
endometrial biopsy, which had been performed as an office
procedure. Hysteroscopy was not performed prior to surgery.
Before the surgery, the patients were examined by computed
tomography and magnetic resonance imaging. Following the
surgery, asymptomatic patients underwent pelvic examination,
Pap smear, chest radiograph, ultrasonography, and/or determina-
tion of serial tumour markers every 4–6 months. Symptomatic
patients underwent the appropriate examination where indicated.
Statistical methods
Survival and disease-free survival (DFS) curves were obtained by
the Kaplan–Meier method and the survival curves were compared
by nonparametric survival analysis (log-rank test). Variables that
showed a significant association with survival or DFS, and
peritoneal cytology were included in multivariate analysis based
on the Cox-proportional hazards model. Patients who died of other
causes were included as deaths in the survival analysis. Follow-up
continued through 30 November, 2001. These statistical analyses
were performed using the Statview statistical software package
(version 5.0; SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient characteristics
In all, 280 patients met the study criteria, with a mean age of 56
years (range, 27–81 years) and a median length of follow-up of 62
months (range, 12–135 months). Of the patients, 112 who
underwent surgery for endometrial carcinoma (mean age, 57
years) were excluded. Of these, 46 patients had extrauterine disease
including stage III and IV. The remaining patients were excluded
because of uncommon histologic subtype, other simultaneous
malignancies, and/or inadequate cytologic materials. Of the 280
subjects, 48 patients (17%) had positive peritoneal cytology and
232 (83%) had negative cytology. The characteristics of the
patients are summarised in Table 1. The histologic subtypes were
the endometrioid type in 270 cases (96%) and the adenosquamous
type in 10 cases (4%). The FIGO stage was as follows: 35 patients
(12%) had stage IA disease, 123 (44%) had stage IB, 41 (15%) had
stage IC, 5 (2%) had stage IIA, 28 (10%) had stage IIB, and 48
(17%) had stage IIIA. In total, 149 patients (53%) underwent
simple hysterectomy and salpingo-oophorectomy with lymphade-
nectomy; 108 (39%) underwent simple hysterectomy and salpingo-
oophorectomy without lymphadenectomy; and 23 (8%) underwent
radical hysterectomy. Preoperative radiation therapy, chemo-
therapy, and progestin therapy were not administered to any
patient. Only three patients received postoperative adjuvant
therapy. These three patients with stage IIB carcinoma had deep
cervical involvement, and external beam radiotherapy to the whole
pelvis (total dose of 50Gy) was administered postoperatively.
Survival
The cumulative survival was assessed in subgroups according to
peritoneal cytology (positive or negative), age (over 60 years or 60
years and under), histologic grade (grade 1, grade 2, or grade 3),
Table 1 Patient characteristics
Positive cytology Negative cytology
n=48 (%) n=232 (%)
Age (y)
Over 60 12 (25) 76 (33)
60 or under 36 (75) 156 (67)
Histologic grade
Grade 1 34 (81) 147 (63)
Grade 2 10 (17) 56 (24)
Grade 3 4 (2) 29 (13)
Myometrial invasion
Absent 5 (10) 35 (15)
o1/3 20 (42) 106 (46)
1/3–2/3 11 (23) 52 (22)
>2/3 12 (25) 39 (17)
Cervical involvement
Absent 34 (70) 198 (85)
Mucosal 7 (15) 6 (3)
Stromal 7 (15) 28 (12)
Lymph – vascular space invasion
Absent 34 (71) 172 (74)
Present 14 (29) 60 (26)
Lymph node status
Negative 32 (67) 140 (60)
Not resected 16 (33) 92 (40)
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British Journal of Cancer (2003) 88(2), 245–250 & 2003 Cancer Research UKdepth of myometrial invasion (absent, o1=3;1=3   2=3 or 42=3),
cervical involvement (absent, mucosal, or stromal), lymph –
vascular space invasion (absent or present), and lymph node status
(not metastasised or not resected). The 5-year survival rate was
91% among the positive cytology group and 95% among the
negative cytology group (Figure 1). There was no significant
difference in survival between patients with positive or negative
cytology (log-rank, P¼0.42). There were no significant differences
in the survival of patients in subgroups according to cervical
involvement (log-rank, P¼0.89), lymph– vascular space invasion
(log-rank, P¼0.40), and lymph node status (log-rank, P¼0.79).
Significant differences in survival were found among patients in
subgroups according to age, myometrial invasion and histologic
grade. Multivariate analysis of testing for differences in survival
among the subgroups of cytology, age, depth of myometrial
invasion, and histologic grade was performed. The proportional
hazards model revealed that only histologic grade was an
independent prognostic factor and positive cytology was not an
independent adverse prognostic factor (Table 2).
Similarly, the DFS was assessed in the same subgroups. The DFS
at 36 months was 90% among the patients with positive cytology,
compared with 94% among the patients with negative cytology,
and this difference was not significant (log-rank, P¼0.52)
(Figure 2). Univariate analysis also revealed no significant
differences in the DFS of patients in subgroups according to
lymph – vascular space invasion (log-rank, P¼0.29), and lymph
node status (log-rank, P¼0.60). There were significant differences
in the DFS of patients in subgroups according to age, myometrial
invasion, histologic grade, and cervical involvement. Among these
significant subgroups and the subgroup according to peritoneal
cytology, the Cox-proportional hazards model showed that only
histologic grade was an independent prognostic factor for DFS,
and that positive cytology was not an independent factor (Table 3).
Prognosis and failure sites
Among the 280 patients, 14 patients (5%) suffered tumour
recurrence. Table 4 presents the clinical characteristics of the
recurrent patients. Peritoneal spread was found in only 20% (one
out of five) of the patients with positive cytology who recurred, and
the affected site was outside the peritoneal cavity in the remaining
13 patients.
DISCUSSION
In the past 20 years, over 50 reports on the significance of positive
peritoneal cytology in endometrial carcinoma have been pub-
lished, and many conflicting results have appeared in the
literature. Based on studies that found that positive cytology is
an independent adverse prognostic factor (Harouny et al, 1988;
Mazurka et al, 1988; Brewington et al, 1989; Turner et al, 1989;
Sutton, 1990; Morrow et al, 1991; Grigsby et al, 1992; Kadar et al,
1994; Descamps et al, 1997; Kashimura et al, 1997; Obermair et al,
2001), postoperative adjuvant therapy was recommended for
patients with positive peritoneal cytology. Progestins, whole
abdominal external radiation, intraperitoneal radioactive chromic
phosphate (
32P), and multiagent chemotherapy have been
proposed. The efficacy of these modalities for treating positive
cytology in the absence of other evidence of extrauterine disease is
not universally accepted (McLellan et al, 1989; Lurain, 1992). On
the other hand, investigators who did not find that malignant
peritoneal cytology is a significant prognostic factor found no
benefit of adjuvant therapy in patients with positive cytology in the
absence of other adverse prognostic factors (Yazigi et al, 1983;
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Figure 1 Survival of patients with endometrial carcinoma confined to
the uterus according to the presence or absence of malignant peritoneal
cytology.
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Figure 2 DFS in patients with endometrial carcinoma confined to the
uterus according to the presence or absence of malignant peritoneal
cytology.
Table 2 Univariate analysis and multivariate proportional hazards model
for survival
Univariate
Multivariate
P-value Hazard ratio 95% CI
a P-value
Peritoneal cytology 0.42
Positive 1.82 0.56–5.86 0.31
Age (y) 0.0045
Over 60 2.50 0.93–6.71 0.06
Myometrial invasion 0.02
o1/3 0.97 0.10–8.66 0.97
1/3–2/3 0.65 0.061–7.07 0.72
>2/3 1.27 0.13–12.35 0.83
Histologic grade o0.0001
Grade 2 3.28 0.81–13.21 0.09
Grade 3 11.02 3.02–40.27 0.0003
a95% confidence interval.
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British Journal of Cancer (2003) 88(2), 245–250 & 2003 Cancer Research UKHernandez et al, 1985; Konski et al, 1988; Hirai et al, 1989; Lurain
et al, 1989; Grimshaw et al, 1990; Kadar et al, 1992; Kennedy et al,
1993; Ayhan et al, 1994; Ebina et al, 1997; Yalman et al, 2000). This
discrepancy is probably because of the following: (1) the reported
incidence of positive cytology was approximately 10% and the
number of subjects was small; (2) the difference between the
surgical stage and the clinical stage was not always distinguished;
(3) various modalities of preoperative and/or postoperative
therapies were used; (4) in the statistical analysis, multivariate
analysis was not always employed; (5) the objectivity of the
cytopathologic diagnosis was not always guaranteed; and (6) a
prospective study has not been performed.
The prognosis of endometrial carcinoma appears to be good,
and an overall 5-year survival rate of 76% can be achieved
(Creasman et al, 2001) because the majority of patients with
endometrial carcinoma have localised, low-grade disease at the
time of primary treatment. Indeed, our data indicated that the 5-
year survival rate of patients with endometrial carcinoma confined
to the uterus was above 90% regardless of positive peritoneal
cytology. Additionally, the Cox-proportional hazards model
demonstrated that positive peritoneal cytology was not an
independent adverse factor for survival and DFS. Although the
number of patients in our study was not as large as that in some
other studies, all patients were surgically staged and received no
preoperative therapy. Only three patients (1%) were treated with
postoperative adjuvant therapy. Considering the above facts, it is
doubtful whether patients with no extrauterine disease except for
positive peritoneal cytology require more aggressive therapy. As
for the statistical power, it was difficult to evaluate the power
calculation statistically because the number of statistical events
was limited and our study was a retrospective one.
In the study of the Gynecologic Oncology Group (GOG)
reported by Morrow et al (1991), 895 patients with clinical stage
I or II (occult) carcinoma of the endometrium were analysed. In
total, 29% of the patients with positive cytology developed
recurrence compared with 10.5% of the cytology-negative patients,
and a relation between malignant cytology and poor outcome was
demonstrated by a multivariate model. This GOG study included
patients with extrauterine disease, and 42.9% of the patients with
no evidence of extrauterine disease received some form of
postoperative radiotherapy. Turner et al (1989) demonstrated by
multivariate analysis that positive cytology was a poor prognostic
factor for both the 5-year survival rate (84 vs 96%) and
progression-free interval (65% at 5 years vs 96%) among 567
patients with surgical stage I disease. In that study, 28 women
(4.9%) had positive cytology, and the primary treatment was
surgery alone for 90 patients (16%), surgery with preoperative
adjuvant radiotherapy in 409 patients (72%), and surgery with
postoperative adjuvant radiotherapy in 46 patients (8%). Pre-
operative radiotherapy may have affected the surgical stage and
peritoneal cytology of many patients enrolled in that study.
Similarly, in many previous studies that found that positive
peritoneal cytology had no prognostic significance, we found the
same problems; for example, many patients received pre- or
postoperative adjuvant therapy, or multivariate analysis was not
employed. Grimshaw et al (1990) showed that there was no
significant difference in the 5-year survival rate between patients
with positive or negative cytology (80 vs 86%) among 305 surgical
stage I patients. In that study, statistical significance was analysed
with only the Fisher exact test. Kadar et al (1992) demonstrated
that positive cytology did not influence survival if the disease was
confined to the uterus using Cox’s proportional hazards model. In
that study, treatment variables included the use of adjunctive
radiation therapy and the type of radiation therapy used, and 59%
(159 out of 269) of the patients received radiation therapy. In the
present study, no patient received preoperative therapy and only
Table 3 Univariate analysis and multivariate proportional hazards model
for DFS
Univariate
Multivariate
P-value Hazard ratio 95% CI
a P-value
Peritoneal cytology 0.52
Positive 0.83 0.24–2.88 0.77
Age (y) 0.005
Over 60 2.23 0.93–5.32 0.06
Myometrial invasion 0.006
o1/3 1.94 0.23–16.04 0.53
1/3–2/3 2.16 0.23–19.85 0.49
>2/3 3.63 0.39–33.74 0.25
Histologic grade o0.0001
Grade 2 1.32 0.40–4.30 0.63
Grade 3 3.46 1.21–9.92 0.02
Cervical involvement 0.007
Mucosal 3.47 0.86–14.01 0.07
Stromal 0.55 0.12–2.48 0.44
a95% confidence interval.
Table 4 Clinical characteristics of 14 recurrent patients
Patient
no.
Peritoneal
cytology
Histologic
grade
Depth of
invasion
Cervical
involvement
Initial
failure sites
Time to recurrence
(months) Treatment Status
1 Positive 1 >2/3 Mucosal Nodes 24 Not done DOD
b (40)
2 Positive 1 o1/3 Mucosal Peritoneum 9 Chemo AWD
c (39)
3 Positive 2 o1/3 Absent Lung 19 Chemo DOD (22)
4 Positive 3 >2/3 Mucosal Lung 6 Chemo DOD (19)
5 Positive 3 >2/3 Absent Nodes, bone 24 RT
a DOD (26)
6 Negative 1 1/3–2/3 Absent Vagina 4 RT NED
d (116)
7 Negative 1 1/3–2/3 Absent Vagina 26 RT NED (64)
8 Negative 1 >2/3 Stromal Lung, vagina 4 RT, Chemo NED (72)
9 Negative 1 Absent Absent Systemic 26 RT, Chemo DOD (41)
10 Negative 1 >2/3 Stromal Lung 13 Surgery NED (57)
11 Negative 2 >2/3 Absent Lung 33 Not done DOD (42)
12 Negative 2 >2/3 Absent Spleen 24 Surgery AWD (47)
13 Negative 3 >2/3 Absent Bone 11 Not done DOD (13)
14 Negative 3 >2/3 Absent Lung 31 Unknown DOD (40)
aRadiation therapy;
bDead of disease;
cAlive with disease;
dNo evidence of disease.
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British Journal of Cancer (2003) 88(2), 245–250 & 2003 Cancer Research UKthree (1%) of the 280 patients received postoperative adjuvant
therapy.
Positive cytology was not an adverse prognostic factor in
endometrial carcinoma limited to the uterus, and it is unknown
from where these cancer cells were derived. Although there are
insufficient data to reach a conclusion about the source of the
cancer cells in peritoneal washings, the following mechanisms may
be deduced from the literature (McLellan et al, 1989; Lurain, 1992):
(1) result of transtubal transport; (2) direct extension of tumour
through the myometrium; (3) lymphatic metastasis to the
peritoneal cavity; and (4) reflection of multifocal peritoneal occult
spread. The transtubal transport theory seems to be the most
popular. Hirai et al (2001) demonstrated by using a tube that was
inserted into the abdomen during the operation for cytologic
analysis, that positive peritoneal cytology usually disappeared
within a short period of time after the operation (within 14 days)
in patients with limited disease in comparison to patients with
adnexal metastasis. Additionally, as for the failure site in the
present series, peritoneal spread was found in only 20% of the
patients with positive cytology who recurred, and in the remaining
patients, the affected site was outside the peritoneal cavity.
Another study (Lurain et al, 1989) showed that 17% of patients
with stage I disease who had positive cytology suffered recurrence,
and only 20% of these recurrences were within the abdomen. The
above-mentioned findings suggest that malignant cells obtained by
peritoneal washing may not reflect the potential of peritoneal
spread in a significant proportion of endometrial carcinoma cases
unless other extrauterine disease is present.
In most studies including the present study, peritoneal cytology
was analysed by conventional cytopathologic techniques and
morphologic findings. Although cytopathologic findings including
adequate sampling are essential for analysing the prognostic value
of peritoneal cytology, evaluating the objectivity of cytopathologic
diagnosis is difficult. The available data indicated that among 3091
reported cases with clinical stage I disease, the overall incidence of
positive cytology was 11.4% (range, 2.9–29.8%) (McLellan et al,
1989). If the positive rate in a study is rather high, the possibility
that reactive mesothelial cells were confused with malignant cells
must be considered. If the positive rate in a study is too low,
sampling error should be considered. Szpak et al (1981)
demonstrated that the presence of abundant malignant cells
(greater than 1000 cells per 100ml sample) significantly shortened
the time to recurrence. Yanoh et al (1999) proposed that the
findings of endometrial adenocarcinoma cells exhibiting high
cellularity, scalloped edge of cell clusters and isolated cells in
peritoneal cytology could be regarded as a risk factor for intra-
abdominal recurrence. Luo et al (2001) reported that analysis of
peritoneal washings with conventional and immunocytochemical
(MOC-31) staining improved the diagnosis of peritoneal cytology
in endometrial carcinoma, and positive combined cytology was a
prognostic factor. The results of research on these morphological
findings have not yet been widely accepted, and will be worthy of
consideration in the future.
Currently, we believe that the presence of positive peritoneal
cytology is not an independent prognostic factor, and that it does
not seem to reflect the potential of peritoneal spread in patients
with endometrial carcinoma confined to the uterus. Adjuvant
therapy such as chemotherapy, radiation therapy, or progestins
does not appear to be beneficial in these patients at present.
Nonetheless, further investigation and prospective multiinstitu-
tional prospective analyses are needed.
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